This company is engaged in developing innovative targeted anticancer CRIMINAL_CHARGE, conducting clinical_trials globally, and establishing R&D capabilities. It was_founded and incorporated in DATE. The registered_business office of the company is located in CITY, COUNTRY COUNTRY COUNTRY. The company specialises in biopharmaceuticals, offering innovative anticancer CRIMINAL_CHARGE like Riboceranib targeting VEGFR - 2, Pyrotinib inhibiting ORGANIZATION, HER2, and HER4, a G2M inhibitor disrupting CAUSE_OF_DEATH cell division, alongside medical cannabis with cannabinoids, CDK inhibitors for overcoming drug resistance, clinical_trials across phases, R&D services in drug_discovery, medical equipment development, and a commitment_to ethical governance, environmental_sustainability, and social contributions. It positions_itself as a TITLE in biopharmaceutical innovation, focusing_on developing advanced therapies to address critical medical needs in oncology. The company continues_to_expand its market_presence through strategic initiatives in drug development, regulatory approvals, and international collaborations.